美国儿童人群使用15价肺炎球菌结合疫苗的公共卫生影响与成本效果
BACKGROUND: Although use of the 13-valent pneumococcal conjugate vaccine (PCV13) among children has reduced incidence of pneumococcal disease, a considerable burden of disease remains.…
要点
- 模型假设PCV15对两个新增血清型的疫苗效果与PCV13相同。
核心结论
- 在美国常规婴儿免疫程序中以PCV15替代PCV13,预期可进一步降低肺炎球菌病负担并带来可观的社会成本节约。
研究设计与样本
- 评估不同疫苗接种策略下额外预防的肺炎球菌病事件与死亡数、每获得一个质量调整生命年(QALY)的成本及每获得一个生命年的成本。
- 假设PCV15对两个新增血清型(22F和33F)的疫苗效果与PCV13相同。
- PCV15儿童使用成本参考成人使用成本及与制造商的讨论。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although use of the 13-valent pneumococcal conjugate vaccine (PCV13) among children has reduced incidence of pneumococcal disease, a considerable burden of disease remains. PCV15 is a new vaccine that contains pneumococcal serotypes 22F and 33F in addition to serotypes contained in PCV13. To inform deliberations by the Advisory Committee on Immunization Practices on recommendations for PCV15 use among U.S. children, we estimated the health impact and cost-effectiveness of replacing PCV13 with PCV15 within the routine infant immunization program in the United States. We also assessed the impact and cost-effectiveness of a supplementary PCV15 dose among children aged 2-5 years who have already received a full PCV13 series. METHODS: We estimated the incremental number of pneumococcal disease events and deaths averted, costs per quality adjusted life-year (QALY) gained, and costs per life-year gained under different vaccination strategies using a probabilistic model following a single birth cohort of 3.9 million individuals (based on 2020 U.S. birth cohort). We assumed that vaccine effectiveness (VE) of PCV15 against the two additional serotypes was the same as the VE of PCV13. The cost of PCV15 use among children was informed from costs of PCV15 use among adults and from discussions with the manufacturer. RESULTS: Our base case results found that replacing PCV13 with PCV15 prevented 92,290 additional pneumococcal disease events and 22 associated deaths, while also saving $147 million in costs. A supplementary PCV15 dose among children aged 2-5 years who were fully vaccinated with PCV13 prevented further pneumococcal disease events and associated deaths but at a cost of more than $2.5 million per QALY gained. CONCLUSIONS: A further decrease in pneumococcal disease in conjunction with considerable societal cost savings could be expected from replacing PCV13 with PCV15 within the routine infant immunization program in the United States.
引用
- Prasad N, Stoecker C, Xing W, et al. Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States. Vaccine. 2023. PMID: 37012118. doi:10.1016/j.vaccine.2023.03.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。